Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $9.3 million.

  • Iovance Biotherapeutics' Other Non-Current Assets changed N/A to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year change of. This contributed to the annual value of $6.4 million for FY2024, which is 9042.75% down from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Other Non-Current Assets is $9.3 million.
  • Iovance Biotherapeutics' 5-year Other Non-Current Assets high stood at $66.4 million for Q2 2023, and its period low was $5.8 million during Q1 2025.
  • Moreover, its 3-year median value for Other Non-Current Assets was $9.3 million (2025), whereas its average is $27.1 million.
  • Within the past 5 years, the most significant YoY rise in Iovance Biotherapeutics' Other Non-Current Assets was 0.0% (2024), while the steepest drop was 9042.75% (2024).
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Other Non-Current Assets stood at $66.4 million in 2023, then crashed by 90.43% to $6.4 million in 2024, then surged by 45.79% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $10.3 million for Q2 2025, and $5.8 million during Q1 2025.